Recent Company News

• 02:15 AM ET Oct 21, 2025
  

  UCB downgraded to hold from buy at Intron Health (€253.30, 0.00)

• 01:04 AM ET Oct 14, 2025
  

  UCB announces final analysis of OLE study of Fintepla in Lennox-Gastaut syndrome published in Epilepsy and Behavior (€260.00, 0.00)

• 02:59 AM ET Oct 13, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:06 AM ET Oct 13, 2025
  

  UCB announces results highlighting a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) published in Neurology (€256.00, 0.00)

• 03:56 AM ET Oct 08, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (81 total)

• 04:20 AM ET Oct 02, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (99 total)

• 04:38 AM ET Oct 01, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:55 AM ET Oct 01, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (51 total)

• 11:12 AM ET Sep 29, 2025
  

  Street Takeaways - MoonLake Immunotherapeutics Phase 3 VELA-1 and VELA-2 trial results ($6.58, -55.42)

• 04:19 AM ET Sep 29, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (74 total)